Obesity and kidney disease: from population to basic science and the search for new therapeutic targets

Kidney International

Volumn 92, Issue 2, 2017, Pages 313-323

  Whaley Connell, Adam ^a,b   Sowers, James R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

Author keywords

chronic kidney disease; mineralocorticoid receptor; obesity; tubulointerstitial fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; MATRIX METALLOPROTEINASE; MINERALOCORTICOID RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; UVOMORULIN; VIMENTIN; ALDOSTERONE;

AGING; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY FAILURE; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; EPIDEMIC; EPITHELIAL MESENCHYMAL TRANSITION; GLOMERULUS FILTRATION; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; OBESITY; OXIDATIVE STRESS; PANDEMIC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUALITY ADJUSTED LIFE YEAR; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SALT INTAKE; SODIUM ABSORPTION; SODIUM RETENTION; VASODILATATION; ANIMAL; COMPLICATION; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PATHOPHYSIOLOGY;

ALDOSTERONE; ANIMALS; HUMANS; INSULIN RESISTANCE; KIDNEY; KIDNEY FAILURE, CHRONIC; OBESITY; RECEPTORS, MINERALOCORTICOID; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM;

EID: 85015763423     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.12.034     Document Type: Review

References (139)

1. World Kidney Day. Chronic kidney disease. Available at: http://www.worldkidneyday.org/faqs/chronic-kidney-disease. Accessed February 6, 2017.
2. National Kidney Foundation. About chronic kidney disease. Available at: https://www.kidney.org/kidneydisease/aboutckd. Accessed May 5, 2016.
3. National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation. National Chronic Kidney Disease Fact Sheet, 2014. Available at: http://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf. Accessed February 6, 2017.
4. Murphy, D., McCulloch, C.E., Lin, F., et al. Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med 165 (2016), 473–481.
5. Zhang, L., Long, J., Jiang, W., et al. Trends in chronic kidney disease in China. N Engl J Med 375 (2016), 905–906.
6. El Nahas, A.M., Bello, A.K., Chronic kidney disease: the global challenge. Lancet 365 (2005), 331–340.
7. Correa-Rotter, R., Naicker, S., Katz, I.J., et al. Demographic and epidemiologic transition in the developing world: role of albuminuria in the early diagnosis and prevention of renal and cardiovascular disease. Kidney Int 66 (2004), S32–S37.
8. Lozano, R., Naghavi, M., Foreman, K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
9. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
10. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
11. Murray, C.J.L., Barber, R.M., Foreman, K.J., et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 386 (2015), 2145–2191.
12. Carney, E.F., Epidemiology: Global Burden of Disease Study 2013 reports that disability caused by CKD is increasing worldwide. Nat Rev Nephrol, 11, 2015, 446.
13. United States Renal Data System. USRDS 2013 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD, National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases.
14. Tuttle, K.R., Bakris, G.L., Bilous, R.W., et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 37 (2014), 2864–2883.
15. Ferdinand, K.C., Rodriguez, F., Nasser, S.A., et al. Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations. Cardiorenal Med 4 (2014), 1–11.
16. World Health Organization. Global Health Observatory (GHO) data: obesity. Available at: http://www.who.int/gho/ncd/risk_factors/obesity_text/en. Accessed October 22, 2016.
17. Swinburn, B.A., Sacks, G., Hall, K.D., et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 378 (2011), 804–814.
18. Ogden, C.L., Carroll, M.D., Curtin, L.R., et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2295 (2006), 1549–1555.
19. Nielsen, S.J., Siega-Riz, A.M., Popkin, B.M., Trends in energy intake in U.S. between 1977 and 1996: similar shifts seen across age groups. Obes Res 10 (2002), 370–378.
20. U.S. Renal Data System. USRDS 2015 chapter 1: CKD in the general population. Available at: https://www.usrds.org/2015/view/v1_01.aspx. Accessed February 6, 2017.
21. Kramer, H.J., Saranathan, A., Luke, A., et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 17 (2006), 1453–1459.
22. Travers, K., Martin, A., Khankhel, Z., et al. Burden and management of chronic kidney disease in Japan: systematic review of the literature. Int J Nephrol Renovasc Dis 6 (2013), 1–13.
23. Iseki, K., Ikemiya, Y., Kinjo, K., et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65 (2004), 1870–1876.
24. Hsu, C.Y., McCulloch, C.E., Iribarren, C., et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 144 (2006), 21–28.
25. Ejerblad, E., Fored, M.C., Lindblad, P., et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 17 (2006), 1695–1702.
26. Fox, C.S., Larson, M.G., Leip, E.P., et al. Predictors of new-onset kidney disease in a community-based population. JAMA 291 (2004), 844–850.
27. Kramer, H., Luke, A., Bidani, A., et al. Obesity and prevalent and incident CKD: The Hypertension Detection and Follow-Up Program. Am J Kidney Dis 46 (2005), 587–594.
28. Yamagata, K., Ishida, K., Sairenchi, T., et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 71 (2007), 159–166.
29. Ishizaka, N., Ishizaka, Y., Toda, E., et al. Association between obesity and chronic kidney disease in Japanese: differences in gender and hypertensive status. Hypertens Res 30 (2007), 1059–1064.
30. Praga, M., Hernandez, E., Herrero, J.C., et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 58 (2000), 2111–2118.
31. Bonnet, F., Deprele, C., Sassolas, A., et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 37 (2001), 720–727.
32. Pinto-Sietsma, S.J., Mulder, J., Janssen, W.M., et al. The PREVEND study group. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 133 (2000), 585–591.
33. Verhave, J.C., Hillege, H.L., Burgerhof, J.G.M., et al. The PREVEND study group. Impact of sodium intake on urinary albumin excretion is enhanced by obesity. J Int Med 13 (2002), 661–662A.
34. De Jong, P.E., Verhave, J.C., Pinto-Sietsma, S.J., Hillege, H.L., Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 26 (2002), S21–S24.
35. Chen, J., Muntner, P., Hamm, L.L., et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140 (2004), 167–174.
36. Kurella, M., Lo, J.C., Chertow, G.M., The metabolic syndrome and the risk of chronic kidney disease among non-diabetic adults. J Am Soc Nephrol 16 (2005), 2134–2140.
37. Sjöström, L., Peltonen, M., Jacobson, P., et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311 (2014), 2297–2304.
38. Maggard-Gibbons, M., Maglione, M., Livhits, M., et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA 309 (2013), 2250–2261.
39. Navaneethan, S.D., Yehnert, H., Moustarah, F., et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4 (2009), 1565–1574.
40. Bolignano, D., Zoccali, C., Effects of weight loss on renal function in obese CKD patients: A systematic review. Nephrol Dial Transplant 28 (2013), 82–98.
41. Chang, A.R., Chen, Y., Still, C., et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int 90 (2016), 164–171.
42. Porter, L.E., Hollenberg, N.K., Obesity, salt intake and renal perfusion in healthy humans. Hypertension 32 (1998), 144–148.
43. Chagnac, A., Weinstein, T., Korzets, A., et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278 (2000), F817–F822.
44. Reisin, E., Messerli, F.G., Ventura, H.O., Frohlich, E.D., Renal haemodynamic studies in obesity hypertension. J Hypertens 5 (1987), 397–400.
45. Ribstein, J., du Cailar, G., Mimran, A., Combined renal effects of overweight and hypertension. Hypertension 26 (1995), 610–615.
46. Jindal, A., Brietzke, S., Sowers, J.R., Obesity and the cardiorenal metabolic syndrome: therapeutic modalities and their efficacy in improving cardiovascular and renal risk factors. Cardiorenal Med 2 (2012), 314–317.
47. Hall, J.E., Brands, M.W., Dixon, W.N., et al. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 22 (1993), 292–299.
48. Henegar, J.R., Bigler, S.A., Henegar, L.K., et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 12 (2001), 1211–1217.
49. Kambham, N., Markowitz, G.S., Valeri, A.M., et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59 (2001), 1498–1509.
50. Wisse, B.E., The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15 (2004), 2792–2800.
51. Zoccali, C., Mallamaci, F., Tripepi, G., Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int 84 (2003), 65–68.
52. Aizawa-Abe, M., Ogawa, Y., Masuzaki, H., et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 105 (2000), 1243–1252.
53. Wolf, G., Hamann, A., Han, D.C., et al. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 56 (1999), 860–872.
54. Sharma, K., Ramachandrarao, S., Qiu, G., et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118 (2008), 1645–1656.
55. Yang, J., Lin, S.C., Chen, G., et al. Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. J Am Soc Nephrol 24 (2013), 1644–1659.
56. Khan, S.B., Cook, H.T., Bhangal, G., et al. Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 67 (2005), 1812–1820.
57. Guo, G., Morrissey, J., McCracken, R., et al. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol 280 (2001), F777–F785.
58. Klahr, S., Morrissey, J., Progression of chronic renal disease. Am J Kidney Dis 41 (2003), S3–S7.
59. Greenfield, J.R., Campbell, L.V., Insulin resistance and obesity. Clin Dermatol 22 (2004), 289–295.
60. Pulakat, L., Demarco, V.G., Whaley-Connell, A., Sowers, J.R., The impact of overnutrition on insulin metabolic signaling in the heart and the kidney. Cardiorenal Med 1 (2011), 102–112.
61. Rocchini, A.P., Marker, P., Cervenka, T., Time course of insulin resistance associated with feeding dogs a high-fat diet. Am J Physiol 272 (1997), E147–E154.
62. Muniyappa, R., Sowers, J.R., Endothelial insulin and IGF-1 receptors: when yes means NO. Diabetes 61 (2012), 225–227.
63. Pandey, G., Makhija, E., George, N., et al. Insulin regulates nitric oxide production in the kidney collecting duct cells. J Biol Chem 290 (2015), 5582–5591.
64. Manhiani, M.M., Cormican, M., Brands, M.W., Chronic sodium-retaining action of insulin in diabetic dogs. Am J Physiol Renal Physiol 300 (2011), F957–F965.
65. Bell, T.D., DiBona, G.F., Biemiller, R., Brands, M.W., Continuously measured renal blood flow does not increase in diabetes if nitric oxide synthesis is blocked. Am J Physiol Renal Physiol 295 (2008), F1449–F1456.
66. Zeng, G., Quon, M.J., Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98 (1996), 894–898.
67. Kocyigit, I., Taheri, S., Sener, E.F., et al. Endothelial nitric oxide synthase gene expression is associated with hypertension in autosomal dominant polycystic kidney disease. Cardiorenal Med 4 (2014), 269–279.
68. Jia, G., Aroor, A.R., Sowers, J.R., Arterial stiffness: a nexus between cardiac and renal disease. Cardiorenal Med 4 (2014), 60–71.
69. Hayashi, K., Kanda, T., Homma, K., et al. Altered renal microvascular response in Zucker obese rats. Metab Clin Exp 51 (2002), 1553–1561.
70. Guo, M., Ricardo, S.D., Deane, J.A., et al. A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat 207 (2005), 813–821.
71. Hall, J.E., Brands, M.W., Dixon, W.N., Smith, M.J., Obesity-induced hypertension: renal function and systemic hemodynamics. Hypertension 22 (1993), 292–299.
72. Hayden, M.R., Whaley-Connell, A., Sowers, J.R., Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 25 (2005), 553–569.
73. Mohan, S., Reddick, R.L., Musi, N., et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest 88 (2008), 515–528.
74. Xu, J., Keeton, A.B., Franklin, J.L., et al. Insulin enhances growth hormone induction of the MEK/ERK signaling pathway. J Biol Chem 281 (2006), 982–992.
75. Lupia, E., Elliot, S.J., Lenz, O., et al. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes 48 (1999), 1638–1644.
76. Hall, J.E., do Carmo, J.M., da Silva, A.A., et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 116 (2015), 991–1006.
77. Giacchetti, G., Faloia, E., Mariniello, B., et al. Overexpression of the renin-angiotensin system in human visceral adipose-tissue in normal and overweight subjects. Am J Hypertens 15 (2002), 381–388.
78. Serazin-Leroy, V., Morot, M., de Mazancourt, P., et al. Androgen regulation and site specificity of angiotensinogen gene expression and secretion in rat adipocytes. Am J Physiol Endocrinol Metab 279 (2000), E1398–E1405.
79. Dusserre, E., Moulin, P., Vidal, H., Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose-tissues. Biochim Biophys Acta 1500 (2000), 88–96.
80. Zhang, L., Chen, X., Hsieh, T.J., et al. Hyperglycemia induces insulin resistance on angiotensinogen gene expression in diabetic rat kidney proximal tubular cells. J Endocrinol 172 (2002), 333–344.
81. Anderson, P.W., Zhang, X.Y., Tian, J., et al. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int 50 (1996), 745–753.
82. Nickenig, G., Roling, J., Strehlow, K., et al. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 98 (1998), 2453–2460.
83. Border, W.A., Noble, N.A., Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 31 (1998), 181–188.
84. Matsuo, S., Lopez-Guisa, J.M., Cai, X., et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67 (2005), 2221–2238.
85. Ruiz-Ortega, M., Rupérez, M., Esteban, V., et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21 (2006), 16–20.
86. Carvajal, G., Rodríguez-Vita, J., Rodrigues-Díez, R., et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 74 (2008), 585–595.
87. Fintha, A., Sebe, A., Masszi, A., et al. Angiotensin II activates plasminogen activator inhibitor-I promoter in renal tubular epithelial cells via the AT1 receptor. Acta Physiol Hung 94 (2007), 19–30.
88. Li, J.H., Zhu, H.J., Huang, X.R., Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 13 (2002), 1464–1472.
89. Gewin, L., Bulus, N., Mernaugh, G., et al. TGF-{beta} receptor deletion in the renal collecting system exacerbates fibrosis. J Am Soc Nephrol 21 (2010), 1334–1343.
90. Sharma, K., Jin, Y., Guo, J., Ziyadeh, F.N., Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45 (1996), 522–530.
91. Basile David, P., Is angiotensin II's role in fibrosis as easy as PAI(-1)?. Kidney Int 58 (2000), 460–461.
92. Kalluri, R., Neilson, E.G., Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112 (2003), 1776–1784.
93. Ishidoya, S., Morrissey, J., McCracken, R., et al. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47 (1995), 1285–1294.
94. Morrissey, J., Klahr, J.S., Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol 276 (1999), F39–F45.
95. Whaley-Connell, A., Habibi, J., Panfili, Z., et al. Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol 34 (2011), 115–125.
96. Yang, J., Liu, J.Y., Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 159 (2001), 1465–1475.
97. Catania, J.M., Chen, G., Parrish, A.R., Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292 (2007), F905–F911.
98. Henger, A., Kretzler, M., Doran, P., et al. Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int 65 (2004), 904–917.
99. Lee, J.M., Dedhar, S., Kalluri, R., Thompson, E.W., The epithelial-mesenchymal transition: newinsights in signalling, development, and disease. J Cell Biol 172 (2006), 973–981.
100. McLennan, S.V., Kelly, D.J., Cox, A.J., Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 45 (2002), 268–275.
101. Sun, S.Z., Wang, Y., Li, Q., et al. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chin Med J (Engl) 119 (2006), 814–821.
102. Fried, L.F., Emanuele, N., Zhang, J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
103. Mann, J.F.E., Schmieder, R.E., McQueen, M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008), 547–553.
104. Parving, H.-H., Brenner, B.M., McMurray, J.J.V., et al., ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
105. Jonk, A.M., Houben, A.J., de Jongh, R.T., et al. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology 22 (2007), 252–260.
106. Rao, A., Pandya, V., Whaley-Connell, A., Obesity and insulin resistance in resistant hypertension: implications for the kidney. Adv Chronic Kidney Dis 22 (2015), 211–217.
107. Sarzani, R., Guerra, F., Mancinelli, L., et al. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am J Hypertens 25 (2012), 818–826.
108. Schjoedt, K.J., Andersen, S., Rossing, P., et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47 (2004), 1936–1939.
109. Sowers, J.R., Whaley-Connell, A., Hayden, M.R., The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med 1 (2011), 5–12.
110. Adabag, S., Huxley, R.R., Lopez, F.L., et al. Obesity related risk of sudden cardiac death in the atherosclerosis risk in communities study. Heart 101 (2015), 215–221.
111. Chen, J., Muntner, P., Hamm, L.L., et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14 (2003), 469–477.
112. Stengel, B., Tarver-Carr, M.E., Powe, N.R., et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 14 (2003), 479–487.
113. Kidambi, S., Kotchen, J.M., Krishnaswami, S., et al. Aldosterone contributes to blood pressure variance and to likelihood of hypertension in normal-weight and overweight African Americans. Am J Hypertens 22 (2009), 1303–1308.
114. Rocchini, A.P., Katch, V.L., Grekin, R., et al. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 57 (1986), 613–618.
115. Briones, A.M., Nguyen Dinh Cat, A., Callera, G.E., et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59 (2012), 1069–1078.
116. Nagase, M., Yoshida, S., Shibata, S., et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 17 (2006), 3438–3446.
117. Brown, N.J., Nakamura, S., Ma, L., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58 (2000), 1219–1227.
118. Habibi, J., Hayden, M.R., Ferrario, C.M., et al. Salt loading promotes kidney injury via fibrosis in young female Ren2 rats. Cardiorenal Med 4 (2014), 43–52.
119. Brown, N.J., Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9 (2013), 459–469.
120. Calhoun, D.A., Jones, D., Textor, S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51 (2008), 1403–1419.
121. Epstein, M., Williams, G.H., Weinberger, M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1 (2006), 940–951.
122. Mehdi, U.F., Adams-Huet, B., Raskin, P., et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20 (2009), 2641–2650.
123. Brown, N.J., Kim, K.S., Chen, Y.Q., et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85 (2000), 336–344.
124. Greene, E.L., Kren, S., Hostetter, T.H., Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98 (1996), 1063–1068.
125. Shibata, S., Nagase, M., Yoshida, S., et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49 (2007), 355–364.
126. Terada, Y., Kobayashi, T., Kuwana, H., et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol 16 (2005), 2296–2305.
127. Huang, W., Xu, C., Kahng, K.W., et al. Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 294 (2008), F1287–F1295.
128. Drumm, K., Kress, T.R., Gassner, B., et al. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell Physiol Biochem 17 (2006), 21–28.
129. Krug, A.W., Papavassiliou, F., Hopfer, U., et al. Aldosterone stimulates surface expression of NHE3 in renal proximal brush borders. Pflugers Arch 446 (2003), 492–496.
130. Salyer, S.A., Parks, J., Barati, M.T., et al. Aldosterone regulates Na(+), K(+) ATPase activity in human renal proximal tubule cells through mineralocorticoid receptor. Biochim Biophys Acta 1833 (2013), 2143–2152.
131. Blasi, E.R., Rocha, R., Rudolph, A.E., et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 (2003), 1791–1800.
132. Kawarazaki, H., Ando, K., Fujita, M., et al. Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. Am J Physiol Renal Physiol 300 (2011), F1402–F1409.
133. Bender, S.B., DeMarco, V.G., Padilla, J., et al. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension 65 (2015), 1082–1088.
134. Johar, S., Cave, A.C., Narayanapanicker, A., et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20 (2006), 1546–1548.
135. Wei, Y., Whaley-Connell, A.T., Habibi, J., et al. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 53 (2009), 158–165.
136. Caprio, M., Newfell, B.G., la Sala, A., et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102 (2008), 1359–1367.
137. Jeong, Y., Chaupin, D.F., Matsushita, K., et al. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA 106 (2009), 3782–3787.
138. Usher, M.G., Duan, S.Z., Ivaschenko, C.Y., et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120 (2010), 3350–3364.
139. Rickard, A.J., Morgan, J., Tesch, G., et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54 (2009), 537–543.